𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect

✍ Scribed by Stéphane Auroy; Marie-Françoise Avril; Agnès Chompret; Danièle Pham; Alisa M. Goldstein; Giovanna Bianchi-Scarrà; Thierry Frebourg; Pascal Joly; Alain Spatz; Carole Rubino; Florence Demenais; Brigitte Bressac-de Paillerets

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
122 KB
Volume
32
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Multiple primary cancers are one of the hallmarks of inherited predisposition. Outside the familial context, multiple primary tumors could be related either to germline de novo mutations or to low‐penetrance mutations, in predisposing genes. We selected 100 patients who displayed multiple primary melanoma (MPM) without any known melanoma cases recorded within their families and looked for germline mutations in the two melanoma‐predisposing genes identified to date, CDKN2A and CDK4 exon 2. Nine patients (9%) had germline mutations in CDKN2A, whereas none carried germline mutations in exon 2 of CDK4. Seven cases displayed a recurrent missense mutation, G101W, already described in more than 20 melanoma‐prone families; one case carried a missense mutation never reported to date (P114S), and the last case was a carrier of a 6 bp insertion at nucleotide 57 resulting in a duplication of codons 18 and 19. To ascertain whether the G101W was a mutational hot spot for de novo mutations or a common founder mutation, we genotyped eight microsatellite markers flanking the CDKN2A gene. After allowing for recombination over time, haplotype sharing provided evidence for an original G101W mutation common to 6 out of 7 sporadic MPM cases. Therefore, it can be concluded that de novo germline CDKN2A mutations associated with MPM are rare. © 2001 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

New founder germline mutations of CDKN2A
New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment
✍ Caroline Kannengiesser; Stéphane Dalle; Marie-Thérèse Leccia; Marie Françoise Av 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB 👁 1 views

## Abstract Germline mutations in the __CDKN2A__ gene have been shown to predispose individuals to cutaneous malignant melanoma. Here, we describe three melanoma‐prone families and one isolated patient affected by multiple melanoma who carried a tandem germline mutation of __CDKN2A__ at the nucleot

Patients with both pancreatic adenocarci
Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations
✍ Geeta Lal; Ling Liu; David Hogg; Norman J. Lassam; Mark S. Redston; Steven Galli 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

Germline mutations of the CDKN2A tumor suppressor gene have been identified in melanoma kindreds linked to 9p21, and pancreatic adenocarcinoma is the second most common malignancy in some of these families. We hypothesized that unselected patients with both primary cancers, i.e., pancreatic cancer a

Population-based prevalence of CDKN2A an
Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas
✍ Per Helsing; Dag Andre Nymoen; Sarah Ariansen; Solrun J. Steine; Lovise Maehle; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 256 KB 👁 1 views

## Abstract The presence of multiple primary cutaneous melanomas (MPM) has been advocated as guidance to identifying melanoma families. Frequencies of __CDKN2A__ mutations in materials of sporadic MPM cases from pigmented lesion clinics vary between 8 and 15%. Patients with MPM have therefore been

The M53I mutation in CDKN2A is a founder
The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry
✍ Julie Lang; Nicholas Hayward; David Goldgar; Hensin Tsao; David Hogg; Jane Palme 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

## Abstract Germline mutations in the tumor suppressor gene __CDKN2A__ have been shown to predispose to cutaneous malignant melanoma. The M53I mutation is the most common __CDKN2A__ mutation identified in Scottish melanoma patients and is also found in a small number of families in other countries.

CDKN2A (P16INK4a) and CDK4 mutation anal
CDKN2A (P16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas
✍ Elizabeth A. Holland; Helen Schmid; Richard F. Kefford; Graham J. Mann 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 1 views

Mutation analysis of two genes involved in melanoma susceptibility (CDKN2A/p16 INK4a and CDK4) was undertaken in 131 probands with a family history of melanoma. Screening of all three exons of CDKN2A and exon 2 of CDK4 by single-strand conformation polymorphism (SSCP) analysis and/or direct sequenci